Efficacy and safety of nintedanib 1 docetaxel in lung adenocarcinoma patients (pts) following treatment with immune checkpoint inhibitors (ICIs): Updated results of the ongoing non-interventional study (NIS) VARGADO

被引：0
|
作者：
Grohe, C. [1 ]
Gleiber, W. [2 ]
Haas, S. [3 ,4 ]
Krueger, S. [5 ]
Schulze, M. [6 ]
Atz, J. [7 ]
Kaiser, R. [7 ]
机构：
[1] ELK Berlin, Dept Pneumol, Berlin, Germany
[2] Univ Hosp Frankfurt, Pneumol Allergol, Frankfurt, Germany
[3] FEK, Clin Haematol, Neumunster, Germany
[4] FEK, Clin Oncol & Nephrol, Neumunster, Germany
[5] Florence Nightingale Hosp, Dept Pulmonol Allergol Sleep Med & Resp Care, Dusseldorf, Germany
[6] Ambulante Onkol Ostsachsen, Zittau, Germany
[7] Boehringer Ingelheim Pharma GmbH & Co KG, Med Affairs Oncol, Ingelheim, Germany
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1505P
引用
收藏
页码：618 / 618
页数：1
相关论文
共 50 条
  • [21] Results of the non-interventional TARGET study: Efficacy and safety of nilotinib in CML patients (pts) failing prior therapy in routine healthcare
    Dengler, J.
    Mueller, M. C.
    Buss, E.
    le Coutre, P.
    Stegelmann, F.
    Ulshoefer, T.
    Sauer, A.
    Schardt, C.
    Reichert, D.
    Schwinger, U.
    Grunewald, R.
    Waller, C.
    Meincke, M.
    Rupprecht, S.
    Tesch, H.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 56 - 56
  • [22] Interim results of a multicentre, non-interventional study (NIS) on the tolerability and efficacy of octagam® 5% and octagam® 10% in patients with immune thrombocytopenia (ITP)
    Dengler, J.
    Debes, A.
    U., Muenster
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 91 - 91
  • [23] A non-interventional biomarker study in patients (pts) with nonsmall cell lung cancer (NSCLC) of adenocarcinoma histology who are treated with nintedanib according to the approved label (LUMEBioNIS)
    Reck, M.
    Staal-van den Brekel, A. J.
    Mellemgaard, A.
    Morsli, N.
    Ellingboe, A-M.
    Kaiser, R.
    Pietzko, K.
    Kitzing, T.
    Braunger, J.
    Kerr, K.
    ANNALS OF ONCOLOGY, 2017, 28
  • [24] Evaluating safety and efficacy of immune checkpoint inhibitors (ICI) in elderly patients (pts) for advanced cancer treatment: A retrospective study
    Brixius, S. J.
    Meiss, F.
    von Bubnoff, D.
    Zeiser, R.
    Waller, C. F.
    Duyster, J.
    Rawluk, J.
    ANNALS OF ONCOLOGY, 2018, 29
  • [25] Results of the non-interventional TARGET study - Efficacy and safety of nilotinib in routine clinical management of CML patients (pts) failing prior therapy
    Dengler, J.
    Le Coutre, P.
    Stegelmann, F.
    Mueller, M. C.
    Sauer, A.
    Schwinger, U.
    Ulshoefer, T.
    Reichert, D.
    Schneider-Kappus, W.
    Stern, S.
    Vehling-Kaiser, U.
    Waller, C. F.
    Losem, C.
    Meincke, M.
    Frank, O.
    Ottmann, O. G.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 56 - 57
  • [26] Non-interventional LUME-BioNIS study of nintedanib plus docetaxel after chemotherapy in adenocarcinoma non-small cell lung cancer: A subgroup analysis in patients with prior immunotherapy
    Reck, Martin
    Syrigos, Kostas
    Miliauskas, Skaidrius
    Zoechbauer-Mueller, Sabine
    Fischer, Juergen R.
    Buchner, Hannes
    Kitzing, Thomas
    Kaiser, Rolf
    Radonjic, Dejan
    Kerr, Keith
    LUNG CANCER, 2020, 148 : 159 - 165
  • [27] Efficacy and safety of ciclesonide in the treatment of patients with persistent allergic or non-allergic asthma - results of an Austrian non-interventional study
    Burghuber, O. C.
    Koeberl, G.
    Lenk-Feik, S.
    Schantl, M.
    Sander, P.
    Hammer, A.
    WIENER KLINISCHE WOCHENSCHRIFT, 2012, 124 (13-14) : 478 - 479
  • [28] Nintedanib (N) plus docetaxel (D) after immunotherapy in adenocarcinoma non-small cell lung cancer (NSCLC): First results from the non-interventional LUME-BioNIS study
    Reck, M.
    Syrigos, K.
    Miliauskas, S.
    Zoechbauer-Mueller, S.
    Buchner, H.
    Kitzing, T.
    Kerr, K. M.
    ANNALS OF ONCOLOGY, 2019, 30
  • [29] Efficacy and Safety of Nintedanib Plus Docetaxel in Patients with Advanced Lung Adenocarcinoma: Complementary and Exploratory Analyses of the Phase III LUME-Lung 1 Study
    Gottfried, Maya
    Bennouna, Jaafar
    Bondarenko, Igor
    Douillard, Jean-Yves
    Heigener, David F.
    Krzakowski, Maciej
    Mellemgaard, Anders
    Novello, Silvia
    Orlov, Sergei
    Summers, Yvonne
    von Pawel, Joachim
    Stoehr, Julia
    Kaiser, Rolf
    Reck, Martin
    TARGETED ONCOLOGY, 2017, 12 (04) : 475 - 485
  • [30] Efficacy and Safety of Nintedanib Plus Docetaxel in Patients with Advanced Lung Adenocarcinoma: Complementary and Exploratory Analyses of the Phase III LUME-Lung 1 Study
    Maya Gottfried
    Jaafar Bennouna
    Igor Bondarenko
    Jean-Yves Douillard
    David F. Heigener
    Maciej Krzakowski
    Anders Mellemgaard
    Silvia Novello
    Sergei Orlov
    Yvonne Summers
    Joachim von Pawel
    Julia Stöhr
    Rolf Kaiser
    Martin Reck
    Targeted Oncology, 2017, 12 : 475 - 485
12345